(redirected from urokinase)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to urokinase: streptokinase
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
[32] Urokinase + Aspirin 36 versus 35 TABLE 2: Summary of findings and evidence qualities for the main comparisons.
Randrianarisoa et al., "Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus," Scientific Reports, vol.
Ladelund et al., "Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population," Biomarker Insights, vol.
Blasi, "Identification and primary sequence of an unspliced human urokinase Poly(A)+RNA," Proceedings of the National Academy of Sciences of the United States of America, vol.
In 2017, the Sales Value of Urokinase in China Reached CNY 50.56 Million, Representing a CAGR of 7.90% from 2013 to 2017
Systemic routes of administration of thrombolytic drugs Drug name Loading dose Infusion dose Streptokinase 250000 IU, 30 min 100000 IU/h Urokinase 4400 IU, 10 min 4400 IU/kg/h Alteplase (rt-PA) Not needed 50 mg/h * Reteplase Not needed 10 U IV bolus, twice with 30- min interval Tenecteplase Not needed 10000 U bolus single dose in 5-10 seconds ** Drug name Administration time Streptokinase 24 h Urokinase 12 h Alteplase (rt-PA) 2 h Reteplase Tenecteplase * For patients below 65 kg, total dose in 2 h is calculated as 1.5 mg/kg ** Should be administered based on body weight with maximum dose of 50 mg (10000 U tenecteplase)
Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2.
ALS was initiated due to ventricular fibrillation, and a bolus of 1.000.000 IU of urokinase was administered during CPR.
* Urokinase passed through haematoma, drainage tube clamped for 15 mins and then reopened.
Moreover, exposure of colon carcinoma cells to morphine was associated with a significant increase in secretion of urokinase plasminogen activator suggesting a potential association between morphine and the invasive properties of the tumor (9).
Two other plasminogen activators that occur naturally in human circulatory system are the tissue type (tPA) and the urokinase type (uPA).
Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer.